First RSV vaccine candidate shows significant efficacy in older patients

The first respiratory syncytial virus (RSV) vaccine candidate has shown statistically significant and clinically meaningful efficacy in adults aged 60 years and above. The magnitude of effect observed was consistent across RSV A and B strains, key secondary endpoints and in those aged 70 years and above. What is RSV? RSV is a common contagious virus affecting the lungs and breathing passages. It is one of the major remaining infectious diseases for which there is currently no vaccine or specific treatment. Older adults are at high risk for severe disease due to age-related decline in immunity and underlying conditions. RSV